
Novartis in US$465m deal with 3B Pharmaceuticals GmbH
Under the agreement, which foresees US$425m in milestones plus royalities on future sales for 3B Pharmaceuticals GmbH (3BP), Basel-based pharma...

Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Mainz Biomed Partners with Microba Life Sciences
Leveraging a platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases, Microba and Mainz Biomed...

eXmoor Pharma Ltd raises US$35m
The financing of eXmoor Pharma Ltd. was led by new investor Kineticos Ventures and existing investor MVM Partners to help launching...

Algal enzyme synthesizes gasoline building blocks
Deciphering the mechanism of the photoenzyme Fatty acid photodecarboxylase (FAP), a research team co-headed by Frederic Beisson from University...

Glioma drug combo turns tumours hot
Swiss researchers have shrinked one of the most lethal and untreatable types of cancer in mice using a combination treatment that proved safe in five...

Dualyx NV raises €40m in Series A financing
The Series A financing was co-led by Fountain Healthcare Partners, Forbion and Andera Partners and seed investors V-Bio Ventures, BGV, PMV, VIB,...